Gland Pharma (GLAND)

FairStock Score: 67/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor first, so I ask: what am I paying for? Gland Pharma trades at ₹2,970.20, a market cap of ₹48,998 Cr, 43.48 times earnings and 4.72 times book. Its book value is ₹628.68. On Graham's arithmetic, the Graham Number is only ₹801.85, leaving a margin of safety of -127.25%; that tells me the price already discounts much good news. Yet the business has momentum: sales grew 23.03%, profit 35.33%, and five-year revenue CAGR is 16.36%. The latest quarter delivered ₹1,695 Cr sales and ₹261 Cr net profit. Free cash flow is ₹2,633 Cr, debt/equity is just 0.03, Piotroski is 8/9, and Altman Z is 3.39. Those are signs of financial strength, not a fragile balance sheet. The moat is not obvious from these numbers alone; low debt and strong FCF hint at quality, but ROE of 9.26% and ROCE of 11.89% are not elite. Promoter holding of 51.83% aligns owners, and a PEG of 0.43 looks cheap if growth persists. But a 43.48 P/E for modest returns on capital is demanding. The negative EV/EBITDA of -103.60 is odd and I would not treat it as a normal valuation anchor. DCF intrinsic value of ₹8,554.19 implies large upside, but Graham would demand a wider margin of safety before trusting optimistic projections. FairStock Score 67/100 is STEADY, not compellingly cheap. My conclusion: quality growth with a fortress balance sheet, but the price leaves little room for error. I would watch growth durability, returns on capital, and whether cash flow keeps compounding.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer